February 25, 2018 11:19 AM ET

Biotechnology

Company Overview of ABL Biotechnologies Limited

Company Overview

ABL Biotechnologies Limited engages in the discovery and collection of microbes, establishment of compound libraries, and discovery of drug and nutrition targets. It operates through three segments: Formulation, Research and Development, and The DHA project. The company is also involved in conducting research and converting the strains/compounds collected into deliverable active pharmaceutical products. It offers softgel capsules. ABL Biotechnologies Limited was incorporated in 1992 and is based in Chennai, India.

Mataji Complex

Room No. 3, 1st floor

No. 1, wallers lane

Near India silk House, Mount Road

Chennai,  600002

India

Founded in 1992

Key Executives for ABL Biotechnologies Limited

Chairman, Managing Director and Compliance Officer
Chief Financial Officer and Company Secretary
Head of the Spectrum Division
Head of the Finance & Treasury Functions
Compensation as of Fiscal Year 2017.

ABL Biotechnologies Limited Key Developments

ABL Bio-Technologies Ltd. Announces Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2016

ABL Bio-Technologies Ltd. announced unaudited standalone earnings results for the second quarter and six months ended September 30, 2016. For the quarter, on standalone basis, the company reported loss from operations before other income, finance costs & exceptional items was INR 323,744.000 against INR 330,787.000 a year ago. Net loss for the period from continuing operations was INR 323,744.000 compared to INR 330,787.000 for the same period a year ago. Net loss after minority interest and share of loss of associates was INR 323,744.000 compared to INR 330,787.000 for the same period a year ago. Basic and diluted loss per share before and after extraordinary items was INR 0.039 compared to INR 0.040 for the same period a year ago. For the six months, on standalone basis, the company reported loss from operations before other income, finance costs & exceptional items was INR 641,730.000 against INR 696,652.000 a year ago. Net loss for the period from continuing operations was INR 641,730.000 compared to INR 696,652.000 for the same period a year ago. Net loss after minority interest and share of loss of associates was INR 641,730.000 compared to INR 696,652.000 for the same period a year ago. Basic and diluted loss per share before and after extraordinary items was INR 0.078 as compared to INR 0.085 for the same period last year.

ABL Bio-Technologies Ltd. to Report Q2, 2017 Results on Nov 12, 2016

ABL Bio-Technologies Ltd. announced that they will report Q2, 2017 results on Nov 12, 2016

ABL Bio-Technologies Ltd., Board Meeting, Nov 12, 2016

ABL Bio-Technologies Ltd., Board Meeting, Nov 12, 2016, at 11:30 Indian Standard Time. Agenda: To consider unaudited financial statement for the quarter ended September 30, 2016.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ABL Biotechnologies Limited, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.